Pristinamycin

Pristinamycin, synthesized by Streptomyces pristinaespiralis, is an orally administered antibiotic resembling streptogramin, comprising two distinct components: Pristinamycin I (PI) and Pristinamycin II (PII). This compound exhibits a high efficacy against various antibiotic-resistant pathogens, especially Gram-positive bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant S. aureus (VRSA), and Enterococcus faecium (VREF) [1].

Pristinamycin IA (Mikamycin B) is a cyclo-peptidic macrolactone antibiotic and a substrate for the P-glycoprotein.

Virginiamycin M1 (Pristinamycin IIA) is a macrocyclic lactone peptide antibiotic and is a member of the streptogramin A group of antibiotics.

Pristinamycin IB (Ostreogrycin B2) is a lipopetide antibiotic effective against Gram-positive bacteria.

Pristinamycin IIB is a streptolysin antibiotic that exhibits activity against Gram-positive bacteria.

Pristinamycin IC is an ester peptide antibiotic with activity against Gram-positive bacteria.

Flopristin, a semi-synthetic antibiotic of the streptogramin A class, is a fluorinated derivative of pristinamycin IIB.

Virginiamycin M1 (Standard) is the standard substance of Virginiamycin M1, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Virginiamycin M1 (Pristinamycin IIA) is a macrocyclic lactone peptide antibiotic and is a member of the streptogramin A group of antibiotics.